A Phase Iiib, Open Study To Evaluate The Immunogenicity, Reactogenicity And Safety Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).

Trial Profile

A Phase Iiib, Open Study To Evaluate The Immunogenicity, Reactogenicity And Safety Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Sep 2017 Planned End Date changed from 1 Aug 2018 to 6 Aug 2018.
    • 08 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 6 Aug 2018.
    • 08 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top